Gabapentin Enacarbil
drugOn this page
Also known as ASP-8825ASP8825Gabapentin encarbilGabapentina enacarbiloGabapentine enacarbilGsk-1838262GSK1838262HorizantXP 13512XP-13512XP13512GABAPENTIN-ENACARBIL
Summary
Gabapentin Enacarbil (CHEMBL1628502) is an approved small-molecule prodrug; indicated across 6 conditions including restless legs syndrome and neuralgia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 6 conditions
- Clinical trials: 21
- Chemistry: 329.39 Da · C16H27NO6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1628502 |
| Name | Gabapentin Enacarbil |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 9883933 |
| ChEBI | CHEBI:68840 |
| Molecular formula | C16H27NO6 |
| Molecular weight | 329.39 |
| InChIKey | TZDUHAJSIBHXDL-UHFFFAOYSA-N |
SMILES: CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O
IUPAC name: 2-[1-[[1-(2-methylpropanoyloxy)ethoxycarbonylamino]methyl]cyclohexyl]acetic acid
ChEBI definition: A carbamate ester that is the N-[1-(isobutyryloxy)ethoxy]carbonyl derivative of [1-(aminomethyl)cyclohexyl]acetic acid. The prodrug for gabapentin, used for treatment of neuropathic pain and restless legs syndrome.
Pharmacological roles (ChEBI): prodrug, anticonvulsant, calcium channel blocker.
Also known as: ASP-8825, ASP8825, Gabapentin enacarbil, Gabapentin encarbil, Gabapentina enacarbilo, Gabapentine enacarbil, Gsk-1838262, GSK1838262, Horizant, XP 13512, XP-13512, XP13512
Patent coverage: 192 distinct patent families (522 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| restless legs syndrome | 4 | MONDO:0005391 | EFO:0004270 |
| neuralgia | 4 | MONDO:0021667 | EFO:0009430 |
| diabetic neuropathy | 2 | MONDO:0006626 | EFO:1000783 |
| migraine disorder | 2 | MONDO:0005277 | MONDO:0005277 |
| alcohol abuse | 2 | MONDO:0002046 | MONDO:0007079 |
| kidney disorder | 1 | MONDO:0005240 | EFO:0003086 |
Clinical trials
Total trials: 21.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 6 |
| PHASE2 | 5 |
| PHASE3 | 4 |
| PHASE1 | 4 |
| Not specified | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03082755 | PHASE4 | RECRUITING | Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer’s Disease |
| NCT01668667 | PHASE4 | COMPLETED | Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study |
| NCT01981941 | PHASE4 | COMPLETED | Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment |
| NCT02560766 | PHASE4 | UNKNOWN | An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS |
| NCT02633683 | PHASE4 | UNKNOWN | An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS |
| NCT03053427 | PHASE4 | COMPLETED | A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients |
| NCT00298623 | PHASE3 | COMPLETED | XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome. |
| NCT00333359 | PHASE3 | COMPLETED | XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome. |
| NCT00365352 | PHASE3 | COMPLETED | XP13512 vs. Placebo in Patients With Restless Legs Syndrome. |
| NCT02658188 | PHASE3 | COMPLETED | Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients |
| NCT00508430 | PHASE2 | TERMINATED | ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy |
| NCT00530530 | PHASE2 | COMPLETED | ASP8825 - Study in Patients With Restless Legs Syndrome |
| NCT00742209 | PHASE2 | COMPLETED | Prevention Study in Adult Patients Suffering From Migraine Headaches |
| NCT01332318 | PHASE2 | COMPLETED | Simulated Driving Study in Restless Legs Syndrome |
| NCT02252536 | PHASE2 | COMPLETED | HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder |
| NCT01411124 | PHASE1 | COMPLETED | Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects |
| NCT02629224 | PHASE1 | COMPLETED | ASP8825 - Pharmacokinetics Study in Patients With Impaired Renal Function and Haemodialysis |
| NCT02632331 | PHASE1 | COMPLETED | ASP8825 - A Study to Investigate the Food Effect on the Pharmacokinetics of ASP8825 |
| NCT02633657 | PHASE1 | WITHDRAWN | A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS |
| NCT02642315 | Not specified | COMPLETED | The Effect of Horizant (Gabapentin Enacarbil) on Augmentation |
| NCT02840240 | Not specified | COMPLETED | Effect of Gabapentin Enacarbil on Opioid Consumption and Pain Scores |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: restless legs syndrome, neuralgia